<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31608711</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1-2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>15</StartPage><EndPage>23</EndPage><MedlinePgn>15-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2019.1672750</ELocationID><Abstract><AbstractText><i>Objective</i>: To conduct a phase-II trial using a ranking and selection paradigm where multiple treatments are compared with limited sample size and the best is chosen for a subsequent efficacy trial versus placebo. This strategy can find an effective treatment faster than traditional strategy of conducting larger trials against placebo. <i>Methods</i>: Sixty amyotrophic lateral sclerosis (ALS) participants were randomized 1:1:1 to creatine 30&#x2009;g/day (CRE), tamoxifen 40&#x2009;mg/day (T40), or tamoxifen 80&#x2009;mg/day (T80), with matching placebo. The primary outcome was 38-week change in ALS Functional Rating Scale-Revised (ALSFRS-R), analyzed in a repeated-measures ANOVA. Secondary outcomes included slow vital capacity (SVC), quantitative muscle strength, early drug discontinuation (EDD), adverse events (AEs), and survival. <i>Results</i>: CRE participants experienced higher rates of drug-related AEs (82% vs. 43% T40, 47% T80) and EDD (50% vs. 24% T40, 29% T80). T80 participants experienced slower adjusted mean decline in ALSFRS-R in points/month (-0.80 vs. -0.84 T40, -0.85 CRE) and quantitative muscle strength but not in SVC and higher rates of mortality. <i>Conclusion</i>: Efficacy of T80 ranked numerically superior to CRE and T40 with respect to ALSFRS-R decline. Following the selection paradigm, T80 would be chosen to test against placebo. The approach was not designed to distinguish among treatments that are nearly equally effective or ineffective. If treatments are equivalent, then under the paradigm, it does not matter which treatment is selected. Newer approaches for increasing trial efficiency, including an adaptive platform trial design, may mitigate limitations of the selection design.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Office of the Prescription Drug Monitoring Program, Maryland Department of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>McCance Center for Brain Health at Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Katy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Penn State Health Hershey Medical Center, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhaus</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simionescu</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>SUNY Upstate Medical Center, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimachkie</LastName><ForeName>Mazen M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pestronk</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salameh</LastName><ForeName>Johnny S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>American University of Beirut Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>University of Washington Medical Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Benjamin Rix</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte, NC, USA, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoenfeld</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute and University of Arizona College of Medicine, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Swati</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sean M Healey &amp; AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>094ZI81Y45</RegistryNumber><NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance></Chemical><Chemical><RegistryNumber>MU72812GK0</RegistryNumber><NameOfSubstance UI="D003401">Creatine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):3-4</RefSource><PMID Version="1">31661983</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003401" MajorTopicYN="N">Creatine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Creatine</Keyword><Keyword MajorTopicYN="N">selection design</Keyword><Keyword MajorTopicYN="N">tamoxifen</Keyword><Keyword MajorTopicYN="N">trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31608711</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1672750</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>